Evaluation of MGBG in Metastatic Adenocarcinoma of the Large Bowel

Evaluation of 5-FU vs. a Phase II drug in metastatic adenocarcinoma of the large bowel: Southwest Oncology Group (SWOG) study 7940.

L Leichman;C Fabian;R O'Bryan;JT Guy;W Fletcher;R Shildt;JD McCracken;T Chen ASCO #C-469

AZQ in the treatment of colon cancer - A Southwest Oncology Group study.

R Shildt;J Bonnet;W Fletcher ASCO #C-496

Southwest Oncology Group experience with 5-fluorouracil in carcinoma of the colon.

JD McCracken;TT Chen;LP Leichman;VK Vaitkevicius 13th International Congress of Chemotherapy (Vienna, September 2, 1983), Part 259, SE 12.1 20-8

Southwest Oncology Group Phase II studies with Mitoxantrone in nonhematologic malignancies.

RL Stephens;DD Von Hoff;SA Taylor;WA Knight III;RB Livingston;FE Bull;J Cowan;RD Hilgers;CK Osborne;GA Gates;G Clark In: New Anticancer Drugs: Mitoxantrone and Bisantrene . M Rozencweig, et al, eds. New York: Raven Press, 125-30

Cardiotoxicity in patients treated with Mitoxantrone on Southwest Oncology Group Phase II protocols.

GM Clark;LK Tokaz;DD Von Hoff;LL Thoi;CA Coltman Jr Cancer Treat Symp 3:25-30

Methyl-GAG in advanced colon cancer: A Phase II trial of the Southwest Oncology Group.

WA Knight III;DM Loesch;LP Leichman;C Fabian;RM O'Bryan Cancer Treat Rep 66:2099-2100

Phase II trial of Mitoxantrone in previously untreated patients with colorectal adenocarcinoma: A Southwest Oncology Group study.

JD Cowan;DD Von Hoff;B McDonald;RW Talley;JD McCracken;T Chen Cancer Treat Rep 66:1779-1780

Phase II evaluation of Mitoxantrone in previously untreated patients with colorectal cancer.

J Cowan;DD Von Hoff;B McDonald;R Talley;J McCracken ASCO #C-385

Southwest Oncology Group (SWOG) Phase II with mitoxantrone in non-hematologic malignancies.

RL Stephens;G Clark 3rd NCI-EORTC Symposium on New Drugs in Cancer Therapy (October 15-17, 1981), #36